Genmab has entered into a binding agreement to acquire Merus, with both companies’ boards unanimously approving the transaction, which is expected to close in early Q1 2026 pending customary conditions. Through this acquisition, Genmab will gain full ownership of petosemtamab, Merus’ late-stage antibody therapy that has received two Breakthrough Therapy designations and is advancing toward Phase 3 trials in head and neck cancer.
Also Read: Avathon Launches AI Platform for Liquid Bulk Logistics
Interim readouts are anticipated in 2026, with a potential commercial launch as early as 2027. The deal marks a significant milestone in Genmab’s transition to a wholly owned model, expanding its late-stage portfolio and reinforcing its focus on innovative oncology treatments. Following completion, Genmab is positioned to have four proprietary programs with strong commercial potential, supporting its ambition to deliver multiple new product launches by 2027. The acquisition underscores the company’s strategy to diversify its pipeline, accelerate growth, and advance its leadership in the global oncology market.